NASDAQ$RXST
Rxsight Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
RxSight, Inc. reported strong fourth quarter and full-year 2024 financial results, driven by significant increases in Light Adjustable Lens (LAL) sales and Light Delivery Device (LDD) installations, and reaffirmed its 2025 guidance.
RxSight, Inc. achieved a 41% increase in Q4 2024 revenue to $40.2 million, primarily due to a 61% rise in LAL procedure volume and a 46% expansion in LDD installed base. The company also reported a significant improvement in net loss and gross profit margin compared to the previous year.
- Fourth quarter 2024 revenue increased by 41% to $40.2 million, compared to $28.6 million in Q4 2023.
- Gross profit for Q4 2024 was $28.8 million, or 71.6% of revenue, up from $17.7 million or 61.8% in Q4 2023.
- Net loss for Q4 2024 improved to $(5.9) million, or $(0.15) per share, from $(9.2) million, or $(0.26) per share, in Q4 2023.
- Adjusted net earnings for Q4 2024 were $1.3 million, or $0.03 per share, compared to an adjusted net loss of $(4.8) million, or $(0.13) per share, in Q4 2023.
Headline financials
Revenue & EPS history
Rxsight · Revenue · Quarterly
$40.2M
Revenue by segment
Rxsight · $11.4M total across 2 segments · Q2 2022
- LAL Revenue$5.8M—50.9%
- LDD Revenue$5.6M—49.1%
Forward guidance
RxSight, Inc. reiterated its full-year 2025 guidance, projecting continued growth in revenue and gross profit margin, while managing operating expenses.
Tailwinds
- Revenue projected in the range of $185.0 million to $197.0 million, representing implied growth of approximately 32% to 41% compared to 2024.
- Gross margin projected in the range of 71% to 73%, representing an implied increase of 30 bps to 230 bps compared to 2024.
- Operating expenses projected in the range of $165.0 million to $170.0 million, representing an implied increase of 22% to 25% compared to 2024.
- Operating expense guidance includes non-cash expenses in the range of $22.0 million to $25.0 million.
- Management expresses strong conviction in the potential of adjustability to transform the premium cataract market and plans to expand adoption globally.
Headwinds
- Operating expenses are projected to increase, albeit at a slower rate than revenue growth.
- The guidance includes non-cash expenses, which will impact reported net income.
- The company is still in the early stages of realizing its vision for the premium cataract market, indicating potential for ongoing investment and risk.
- No specific negative forward-looking statements were provided in the report.
- The guidance does not provide a specific net income or EPS forecast for 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2024
-1.1%
Avg return
Earnings day
-2.6%
Avg return
5 days after
+2.8%
Avg return
30 days after
45%
9 / 20 earnings
Positive
+15.1%
Q3 2022
Best reaction
-16.1%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.6% | -21.6% | -31.1% | |
| Q4 2025 | -10.1% | -13.5% | -28.9% | |
| Q3 2025 | +8.7% | +16.3% | +46.7% | |
| Q1 2025 | -11.2% | -11.4% | +0.9% | |
| Q4 2024 | -0.8% | -7.8% | -9.1% | |
| Q3 2024 | -12.3% | -16.9% | -21.2% | |
| Q2 2024 | +14.6% | +21.5% | +29.0% | |
| Q1 2024 | +0.8% | -3.8% | -5.0% | |
| Q4 2023 | -5.8% | -3.2% | -10.9% | |
| Q3 2023 | +1.8% | +9.5% | +40.8% | |
| Q2 2023 | -1.5% | -6.3% | -1.8% | |
| Q1 2023 | +9.0% | +18.3% | +34.0% | |
| Q4 2022 | +9.7% | +4.5% | +17.9% | |
| Q3 2022 | +15.1% | +14.6% | +18.1% | |
| Q2 2022 | -2.9% | -8.3% | -13.3% | |
| Q1 2022 | -4.3% | -3.0% | +34.9% | |
| Q4 2021 | +1.4% | -3.2% | +1.8% | |
| Q3 2021 | +3.7% | -0.8% | -4.0% | |
| Q4 2020 | -16.1% | -18.4% | -21.1% | |
| Q2 2021 | -16.1% | -18.4% | -21.1% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro